1. Home
  2. JELD vs TLSA Comparison

JELD vs TLSA Comparison

Compare JELD & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

SELL

Current Price

$0.84

Market Cap

152.7M

ML Signal

SELL

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$0.56

Market Cap

145.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JELD
TLSA
Founded
1960
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.7M
145.1M
IPO Year
2016
2017

Fundamental Metrics

Financial Performance
Metric
JELD
TLSA
Price
$0.84
$0.56
Analyst Decision
Hold
Strong Buy
Analyst Count
3
2
Target Price
$1.23
★ $7.88
AVG Volume (30 Days)
★ 1.2M
488.0K
Earning Date
11-03-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $3,211,181,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.14
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.93
$0.57
52 Week High
$3.27
$1.90

Technical Indicators

Market Signals
Indicator
JELD
TLSA
Relative Strength Index (RSI) 28.94 27.95
Support Level N/A N/A
Resistance Level $1.48 $1.21
Average True Range (ATR) 0.15 0.08
MACD -0.01 -0.02
Stochastic Oscillator 1.56 2.13

Price Performance

Historical Comparison
JELD
TLSA

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: